Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression

Clinical predictors of outcome in a multisite, randomized controlled clinical trial

Sarah H. Lisanby, Mustafa M. Husain, Peter B. Rosenquist, Daniel Maixner, Rosben Gutierrez, Andrew Krystal, William Gilmer, Lauren B. Marangell, Scott Aaronson, Zafiris J. Daskalakis, Randolph Canterbury, Elliott Richelson, Harold A. Sackeim, Mark S. George

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limitations such as small sample sizes and single-site study designs. Data from a multisite sham-controlled trial of the antidepressant efficacy of TMS provided an opportunity to examine predictors of acute outcome. An open-label extension for patients who failed to improve provided the opportunity for confirmatory analysis. Treatment was administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day. Change on the Montgomery-Asberg Depression Rating Scale after 4 weeks was the primary efficacy outcome. A total of 301 patients with nonpsychotic unipolar major depression at 23 centers were randomized to active or sham TMS. Univariate predictor analyses showed that the degree of prior treatment resistance in the current episode was a predictor of positive treatment outcome in both the controlled study and the open-label extension trial. In the randomized trial, shorter duration of current episode was also associated with a better outcome. In the open-label extension study, absence of anxiety disorder comorbidity was associated with an improved outcome, but duration of current episode was not. The number of prior treatment failures was the strongest predictor for positive response to acute treatment with TMS. Shorter duration of current illness and lack of anxiety comorbidity may also confer an increased likelihood of good antidepressant response to TMS.

Original languageEnglish (US)
Pages (from-to)522-534
Number of pages13
JournalNeuropsychopharmacology
Volume34
Issue number2
DOIs
StatePublished - Jan 2009

Fingerprint

Transcranial Magnetic Stimulation
Randomized Controlled Trials
Depression
Antidepressive Agents
Comorbidity
Therapeutics
Depressive Disorder
Prefrontal Cortex
Anxiety Disorders
Treatment Failure
Sample Size
Anxiety

Keywords

  • Clinical trial
  • Major depression
  • Predictors
  • TMS study group
  • Transcranial magnetic stimulation
  • Treatment resistance

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression : Clinical predictors of outcome in a multisite, randomized controlled clinical trial. / Lisanby, Sarah H.; Husain, Mustafa M.; Rosenquist, Peter B.; Maixner, Daniel; Gutierrez, Rosben; Krystal, Andrew; Gilmer, William; Marangell, Lauren B.; Aaronson, Scott; Daskalakis, Zafiris J.; Canterbury, Randolph; Richelson, Elliott; Sackeim, Harold A.; George, Mark S.

In: Neuropsychopharmacology, Vol. 34, No. 2, 01.2009, p. 522-534.

Research output: Contribution to journalArticle

Lisanby, SH, Husain, MM, Rosenquist, PB, Maixner, D, Gutierrez, R, Krystal, A, Gilmer, W, Marangell, LB, Aaronson, S, Daskalakis, ZJ, Canterbury, R, Richelson, E, Sackeim, HA & George, MS 2009, 'Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: Clinical predictors of outcome in a multisite, randomized controlled clinical trial', Neuropsychopharmacology, vol. 34, no. 2, pp. 522-534. https://doi.org/10.1038/npp.2008.118
Lisanby, Sarah H. ; Husain, Mustafa M. ; Rosenquist, Peter B. ; Maixner, Daniel ; Gutierrez, Rosben ; Krystal, Andrew ; Gilmer, William ; Marangell, Lauren B. ; Aaronson, Scott ; Daskalakis, Zafiris J. ; Canterbury, Randolph ; Richelson, Elliott ; Sackeim, Harold A. ; George, Mark S. / Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression : Clinical predictors of outcome in a multisite, randomized controlled clinical trial. In: Neuropsychopharmacology. 2009 ; Vol. 34, No. 2. pp. 522-534.
@article{126c7e9fad96438585e90bababea6ec6,
title = "Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: Clinical predictors of outcome in a multisite, randomized controlled clinical trial",
abstract = "Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limitations such as small sample sizes and single-site study designs. Data from a multisite sham-controlled trial of the antidepressant efficacy of TMS provided an opportunity to examine predictors of acute outcome. An open-label extension for patients who failed to improve provided the opportunity for confirmatory analysis. Treatment was administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120{\%} of motor threshold, for a total of 3000 pulses per day. Change on the Montgomery-Asberg Depression Rating Scale after 4 weeks was the primary efficacy outcome. A total of 301 patients with nonpsychotic unipolar major depression at 23 centers were randomized to active or sham TMS. Univariate predictor analyses showed that the degree of prior treatment resistance in the current episode was a predictor of positive treatment outcome in both the controlled study and the open-label extension trial. In the randomized trial, shorter duration of current episode was also associated with a better outcome. In the open-label extension study, absence of anxiety disorder comorbidity was associated with an improved outcome, but duration of current episode was not. The number of prior treatment failures was the strongest predictor for positive response to acute treatment with TMS. Shorter duration of current illness and lack of anxiety comorbidity may also confer an increased likelihood of good antidepressant response to TMS.",
keywords = "Clinical trial, Major depression, Predictors, TMS study group, Transcranial magnetic stimulation, Treatment resistance",
author = "Lisanby, {Sarah H.} and Husain, {Mustafa M.} and Rosenquist, {Peter B.} and Daniel Maixner and Rosben Gutierrez and Andrew Krystal and William Gilmer and Marangell, {Lauren B.} and Scott Aaronson and Daskalakis, {Zafiris J.} and Randolph Canterbury and Elliott Richelson and Sackeim, {Harold A.} and George, {Mark S.}",
year = "2009",
month = "1",
doi = "10.1038/npp.2008.118",
language = "English (US)",
volume = "34",
pages = "522--534",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression

T2 - Clinical predictors of outcome in a multisite, randomized controlled clinical trial

AU - Lisanby, Sarah H.

AU - Husain, Mustafa M.

AU - Rosenquist, Peter B.

AU - Maixner, Daniel

AU - Gutierrez, Rosben

AU - Krystal, Andrew

AU - Gilmer, William

AU - Marangell, Lauren B.

AU - Aaronson, Scott

AU - Daskalakis, Zafiris J.

AU - Canterbury, Randolph

AU - Richelson, Elliott

AU - Sackeim, Harold A.

AU - George, Mark S.

PY - 2009/1

Y1 - 2009/1

N2 - Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limitations such as small sample sizes and single-site study designs. Data from a multisite sham-controlled trial of the antidepressant efficacy of TMS provided an opportunity to examine predictors of acute outcome. An open-label extension for patients who failed to improve provided the opportunity for confirmatory analysis. Treatment was administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day. Change on the Montgomery-Asberg Depression Rating Scale after 4 weeks was the primary efficacy outcome. A total of 301 patients with nonpsychotic unipolar major depression at 23 centers were randomized to active or sham TMS. Univariate predictor analyses showed that the degree of prior treatment resistance in the current episode was a predictor of positive treatment outcome in both the controlled study and the open-label extension trial. In the randomized trial, shorter duration of current episode was also associated with a better outcome. In the open-label extension study, absence of anxiety disorder comorbidity was associated with an improved outcome, but duration of current episode was not. The number of prior treatment failures was the strongest predictor for positive response to acute treatment with TMS. Shorter duration of current illness and lack of anxiety comorbidity may also confer an increased likelihood of good antidepressant response to TMS.

AB - Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limitations such as small sample sizes and single-site study designs. Data from a multisite sham-controlled trial of the antidepressant efficacy of TMS provided an opportunity to examine predictors of acute outcome. An open-label extension for patients who failed to improve provided the opportunity for confirmatory analysis. Treatment was administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day. Change on the Montgomery-Asberg Depression Rating Scale after 4 weeks was the primary efficacy outcome. A total of 301 patients with nonpsychotic unipolar major depression at 23 centers were randomized to active or sham TMS. Univariate predictor analyses showed that the degree of prior treatment resistance in the current episode was a predictor of positive treatment outcome in both the controlled study and the open-label extension trial. In the randomized trial, shorter duration of current episode was also associated with a better outcome. In the open-label extension study, absence of anxiety disorder comorbidity was associated with an improved outcome, but duration of current episode was not. The number of prior treatment failures was the strongest predictor for positive response to acute treatment with TMS. Shorter duration of current illness and lack of anxiety comorbidity may also confer an increased likelihood of good antidepressant response to TMS.

KW - Clinical trial

KW - Major depression

KW - Predictors

KW - TMS study group

KW - Transcranial magnetic stimulation

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=57849166192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849166192&partnerID=8YFLogxK

U2 - 10.1038/npp.2008.118

DO - 10.1038/npp.2008.118

M3 - Article

VL - 34

SP - 522

EP - 534

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -